MDM2 antagonist nutlin-3 suppresses the proliferation and differentiation of human pre-osteoclasts through a p53-dependent pathway

Giorgio Zauli, Erika Rimondi, Federica Corallini, Roberto Fadda, Silvano Capitani, Paola Secchiero

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

Exposure of human pre-osteoclasts to the MDM2 antagonist Nutlin-3 activated the p53 pathway and significantly decreased the entry of pre-osteoclasts in the S phase in response to RANKL. Moreover, repeated exposure to Nutlin-3 suppressed osteoclastic differentiation, without affecting cell survival at any culture time. Introduction: The p53 oncosuppressor coordinates an intracellular network involved in protection from malignant transformation and cell cycle control; its activation is tightly regulated by the murine double minute 2 (MDM2) gene and p53-MDM2 interaction can be disrupted by selective small molecule inhibitors, the Nutlins. Although the ability of Nutlins to suppress the growth of wildtype p53 tumors has been clearly established, their biological activity in normal cells and tissues has not been extensively studied. Materials and Methods: Peripheral blood mononuclear cell pre-osteoclasts were cultured with macrophagecolony stimulating factor (M-CSF) + RANKL or co-cultured with SaOS-2 osteosarcoma cells in the presence of IL-1β to induce osteoclastic differentiation. Cell cycle was analyzed by BrdU incorporation. The degree of osteoclastic differentiation was monitored at different culture times by TRACP and DAPI staining, as well as by TRACP-5b ELISA. Finally, the role of p53 in mediating the biological activity of Nutlin-3 was studied using specific siRNA. Results: Exposure of human pre-osteoclasts to RANKL induced an early (24 h) increase in the percentage of cells in the S phase, followed by the exit from the cell cycle at later time-points. The simultaneous addition of Nutlin-3 and RANKL dose-dependently decreased the percentage of pre-osteoclasts in the S phase and induced a rapid accumulation of p53 protein coupled with the induction of p53 target genes. Unexpectedly, the administration of Nutlin-3 to pre-osteoclasts at early culture times significantly suppressed the final output of osteoclasts at day 14 of culture. The role of p53 in mediating this biological activity of Nutlin-3 was underscored by gene knockdown experiments, in which the anti-osteoclastic activity of Nutlin-3 was significantly counteracted by siRNA specific for p53. Nutlin-3 also significantly decreased the formation of osteoclasts in a co-culture system of SaOS-2 osteosarcoma and pre-osteoclastic cells. Conclusions: These findings indicate that Nutlin-3 abrogates both pre-osteoclastic proliferation and differentiation through a p53-dependent pathway and may have therapeutic implications for those neoplastic diseases characterized by an abnormal osteoclastic activity.

Original languageEnglish
Pages (from-to)1621-1630
Number of pages10
JournalJournal of Bone and Mineral Research
Volume22
Issue number10
DOIs
Publication statusPublished - Oct 2007

Fingerprint

Osteoclasts
S Phase
p53 Genes
Osteosarcoma
Small Interfering RNA
Cell Cycle
Gene Knockdown Techniques
nutlin 3
Bromodeoxyuridine
Coculture Techniques
Cell Cycle Checkpoints
Interleukin-1
Blood Cells
Cell Survival
Enzyme-Linked Immunosorbent Assay
Staining and Labeling
Growth

Keywords

  • Cell cycle
  • Nutlin-3
  • Osteoclasts
  • p53 pathway
  • RANKL

ASJC Scopus subject areas

  • Surgery

Cite this

MDM2 antagonist nutlin-3 suppresses the proliferation and differentiation of human pre-osteoclasts through a p53-dependent pathway. / Zauli, Giorgio; Rimondi, Erika; Corallini, Federica; Fadda, Roberto; Capitani, Silvano; Secchiero, Paola.

In: Journal of Bone and Mineral Research, Vol. 22, No. 10, 10.2007, p. 1621-1630.

Research output: Contribution to journalArticle

Zauli, Giorgio ; Rimondi, Erika ; Corallini, Federica ; Fadda, Roberto ; Capitani, Silvano ; Secchiero, Paola. / MDM2 antagonist nutlin-3 suppresses the proliferation and differentiation of human pre-osteoclasts through a p53-dependent pathway. In: Journal of Bone and Mineral Research. 2007 ; Vol. 22, No. 10. pp. 1621-1630.
@article{fc31069e7792434bbfbdb69c865d046f,
title = "MDM2 antagonist nutlin-3 suppresses the proliferation and differentiation of human pre-osteoclasts through a p53-dependent pathway",
abstract = "Exposure of human pre-osteoclasts to the MDM2 antagonist Nutlin-3 activated the p53 pathway and significantly decreased the entry of pre-osteoclasts in the S phase in response to RANKL. Moreover, repeated exposure to Nutlin-3 suppressed osteoclastic differentiation, without affecting cell survival at any culture time. Introduction: The p53 oncosuppressor coordinates an intracellular network involved in protection from malignant transformation and cell cycle control; its activation is tightly regulated by the murine double minute 2 (MDM2) gene and p53-MDM2 interaction can be disrupted by selective small molecule inhibitors, the Nutlins. Although the ability of Nutlins to suppress the growth of wildtype p53 tumors has been clearly established, their biological activity in normal cells and tissues has not been extensively studied. Materials and Methods: Peripheral blood mononuclear cell pre-osteoclasts were cultured with macrophagecolony stimulating factor (M-CSF) + RANKL or co-cultured with SaOS-2 osteosarcoma cells in the presence of IL-1β to induce osteoclastic differentiation. Cell cycle was analyzed by BrdU incorporation. The degree of osteoclastic differentiation was monitored at different culture times by TRACP and DAPI staining, as well as by TRACP-5b ELISA. Finally, the role of p53 in mediating the biological activity of Nutlin-3 was studied using specific siRNA. Results: Exposure of human pre-osteoclasts to RANKL induced an early (24 h) increase in the percentage of cells in the S phase, followed by the exit from the cell cycle at later time-points. The simultaneous addition of Nutlin-3 and RANKL dose-dependently decreased the percentage of pre-osteoclasts in the S phase and induced a rapid accumulation of p53 protein coupled with the induction of p53 target genes. Unexpectedly, the administration of Nutlin-3 to pre-osteoclasts at early culture times significantly suppressed the final output of osteoclasts at day 14 of culture. The role of p53 in mediating this biological activity of Nutlin-3 was underscored by gene knockdown experiments, in which the anti-osteoclastic activity of Nutlin-3 was significantly counteracted by siRNA specific for p53. Nutlin-3 also significantly decreased the formation of osteoclasts in a co-culture system of SaOS-2 osteosarcoma and pre-osteoclastic cells. Conclusions: These findings indicate that Nutlin-3 abrogates both pre-osteoclastic proliferation and differentiation through a p53-dependent pathway and may have therapeutic implications for those neoplastic diseases characterized by an abnormal osteoclastic activity.",
keywords = "Cell cycle, Nutlin-3, Osteoclasts, p53 pathway, RANKL",
author = "Giorgio Zauli and Erika Rimondi and Federica Corallini and Roberto Fadda and Silvano Capitani and Paola Secchiero",
year = "2007",
month = "10",
doi = "10.1359/jbmr.070618",
language = "English",
volume = "22",
pages = "1621--1630",
journal = "Journal of Bone and Mineral Research",
issn = "0884-0431",
publisher = "Wiley-Blackwell",
number = "10",

}

TY - JOUR

T1 - MDM2 antagonist nutlin-3 suppresses the proliferation and differentiation of human pre-osteoclasts through a p53-dependent pathway

AU - Zauli, Giorgio

AU - Rimondi, Erika

AU - Corallini, Federica

AU - Fadda, Roberto

AU - Capitani, Silvano

AU - Secchiero, Paola

PY - 2007/10

Y1 - 2007/10

N2 - Exposure of human pre-osteoclasts to the MDM2 antagonist Nutlin-3 activated the p53 pathway and significantly decreased the entry of pre-osteoclasts in the S phase in response to RANKL. Moreover, repeated exposure to Nutlin-3 suppressed osteoclastic differentiation, without affecting cell survival at any culture time. Introduction: The p53 oncosuppressor coordinates an intracellular network involved in protection from malignant transformation and cell cycle control; its activation is tightly regulated by the murine double minute 2 (MDM2) gene and p53-MDM2 interaction can be disrupted by selective small molecule inhibitors, the Nutlins. Although the ability of Nutlins to suppress the growth of wildtype p53 tumors has been clearly established, their biological activity in normal cells and tissues has not been extensively studied. Materials and Methods: Peripheral blood mononuclear cell pre-osteoclasts were cultured with macrophagecolony stimulating factor (M-CSF) + RANKL or co-cultured with SaOS-2 osteosarcoma cells in the presence of IL-1β to induce osteoclastic differentiation. Cell cycle was analyzed by BrdU incorporation. The degree of osteoclastic differentiation was monitored at different culture times by TRACP and DAPI staining, as well as by TRACP-5b ELISA. Finally, the role of p53 in mediating the biological activity of Nutlin-3 was studied using specific siRNA. Results: Exposure of human pre-osteoclasts to RANKL induced an early (24 h) increase in the percentage of cells in the S phase, followed by the exit from the cell cycle at later time-points. The simultaneous addition of Nutlin-3 and RANKL dose-dependently decreased the percentage of pre-osteoclasts in the S phase and induced a rapid accumulation of p53 protein coupled with the induction of p53 target genes. Unexpectedly, the administration of Nutlin-3 to pre-osteoclasts at early culture times significantly suppressed the final output of osteoclasts at day 14 of culture. The role of p53 in mediating this biological activity of Nutlin-3 was underscored by gene knockdown experiments, in which the anti-osteoclastic activity of Nutlin-3 was significantly counteracted by siRNA specific for p53. Nutlin-3 also significantly decreased the formation of osteoclasts in a co-culture system of SaOS-2 osteosarcoma and pre-osteoclastic cells. Conclusions: These findings indicate that Nutlin-3 abrogates both pre-osteoclastic proliferation and differentiation through a p53-dependent pathway and may have therapeutic implications for those neoplastic diseases characterized by an abnormal osteoclastic activity.

AB - Exposure of human pre-osteoclasts to the MDM2 antagonist Nutlin-3 activated the p53 pathway and significantly decreased the entry of pre-osteoclasts in the S phase in response to RANKL. Moreover, repeated exposure to Nutlin-3 suppressed osteoclastic differentiation, without affecting cell survival at any culture time. Introduction: The p53 oncosuppressor coordinates an intracellular network involved in protection from malignant transformation and cell cycle control; its activation is tightly regulated by the murine double minute 2 (MDM2) gene and p53-MDM2 interaction can be disrupted by selective small molecule inhibitors, the Nutlins. Although the ability of Nutlins to suppress the growth of wildtype p53 tumors has been clearly established, their biological activity in normal cells and tissues has not been extensively studied. Materials and Methods: Peripheral blood mononuclear cell pre-osteoclasts were cultured with macrophagecolony stimulating factor (M-CSF) + RANKL or co-cultured with SaOS-2 osteosarcoma cells in the presence of IL-1β to induce osteoclastic differentiation. Cell cycle was analyzed by BrdU incorporation. The degree of osteoclastic differentiation was monitored at different culture times by TRACP and DAPI staining, as well as by TRACP-5b ELISA. Finally, the role of p53 in mediating the biological activity of Nutlin-3 was studied using specific siRNA. Results: Exposure of human pre-osteoclasts to RANKL induced an early (24 h) increase in the percentage of cells in the S phase, followed by the exit from the cell cycle at later time-points. The simultaneous addition of Nutlin-3 and RANKL dose-dependently decreased the percentage of pre-osteoclasts in the S phase and induced a rapid accumulation of p53 protein coupled with the induction of p53 target genes. Unexpectedly, the administration of Nutlin-3 to pre-osteoclasts at early culture times significantly suppressed the final output of osteoclasts at day 14 of culture. The role of p53 in mediating this biological activity of Nutlin-3 was underscored by gene knockdown experiments, in which the anti-osteoclastic activity of Nutlin-3 was significantly counteracted by siRNA specific for p53. Nutlin-3 also significantly decreased the formation of osteoclasts in a co-culture system of SaOS-2 osteosarcoma and pre-osteoclastic cells. Conclusions: These findings indicate that Nutlin-3 abrogates both pre-osteoclastic proliferation and differentiation through a p53-dependent pathway and may have therapeutic implications for those neoplastic diseases characterized by an abnormal osteoclastic activity.

KW - Cell cycle

KW - Nutlin-3

KW - Osteoclasts

KW - p53 pathway

KW - RANKL

UR - http://www.scopus.com/inward/record.url?scp=38449117242&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=38449117242&partnerID=8YFLogxK

U2 - 10.1359/jbmr.070618

DO - 10.1359/jbmr.070618

M3 - Article

C2 - 17592964

AN - SCOPUS:38449117242

VL - 22

SP - 1621

EP - 1630

JO - Journal of Bone and Mineral Research

JF - Journal of Bone and Mineral Research

SN - 0884-0431

IS - 10

ER -